1 Reason This Biotech Stock Could Triple Before Year-End

By Thomas Niel – Mar 29, 2026 at 12:30AM ESTKey PointsViking Therepeutics' VK2735 candidate is a dark horse contender among GLP-1 weight loss drugs.If upcoming late-stage clinical trial results prove positive, Viking's value as a takeover target could rise exponentially.While risky, Viking's high upside potential, along with the relatively short path to its "moment of truth," may make it worthwhile as a small, speculative position.When you think of GLP-1s and investing, the two large pharmaceutical companies benefiting most from this trend may first come to mind. First, there's Novo Nordisk, the first to bring GLP-1 weight loss drugs to market, with Ozempic and Wegovy. Second, there's Eli Lilly, beating Novo Nordisk at its own game, with its Zepbound GLP-1 treatment. Several other big pharma companies, like Pfizer, have their own injectable and oral-based GLP-1 candidates. The market incumbents are also working on orally administered candidates. But what if a lesser-known candidate, from a smaller biotech company, ultimately gives both Novo Nordisk and Lilly a run for their money? ExpandNASDAQ: VKTXViking TherapeuticsToday's Change(-5.05%) $-1.73Current Price$32.52Key Data PointsMarket Cap$3.8BDay's Range$32.37 - $34.1652wk Range$18.92 - $43.15Volume68KAvg Vol3M Let's take a closer look at Viking Therapeutics (VKTX 5.05%), a dark horse contender among GLP-1 stocks, and why this factor could be the stock's key to a threefold surge. Image source: Getty Images. Viking, VK2735, and the $100 billion opportunity It's not just hype that has led pharmaceutical stocks like Novo Nordisk and Eli Lilly to add hundreds of billions to their market caps due to the rise of GLP-1s. Estimates call for the GLP-1 weight loss market to reach annual sales of $100 billion by the start of the next decade, especially if orally administered GLP-1s come to market. This is what gives Viking Therapeutics and its VK2735 candidate so much potential. The injectable version of this drug is currently in phase 3 clinical trials. A phase 2 clinical trial of an orally administered version completed last year. Initial trial results have been highly promising. However, it is phase 3 trials, including a phase 3 trial for the oral version VK2735 scheduled to begin later this year, that could make or break the stock. If subsequent clinical trial results disappoint, the commercial prospects of VK2735, and in turn Viking stock, could plummet. On the flip side, if subsequent trials yield promising results, Viking Therapeutics' share price may skyrocket. If VK2735 is commercially viable, Viking could become an instant takeover target among biotech stocks. Given the market opportunity relative to Viking's small $4 billion market cap, acquisition offers of as much as 3 times Viking's current valuation are not out of the question. In the past, Viking, trading for around $32 per share today, at one point traded at prices nearing $100 per share. A binary bet, so size your position accordingly Make no mistake. The situation with Viking Pharmaceuticals is binary. Either VK2735 moves ahead, or it doesn't. The downside risk is considerably high with this stock. Prior to the emergence of this GLP-1 catalyst, shares traded in the low single digits. Yet while downside potential is massive, so is upside potential. Not only that, the time horizon for Viking's "moment of truth" could be as little as a matter of months. Compare that to other biotech stocks, which are years away from finding out whether they have struck oil or merely drilled a dry well. By no means should you bet the ranch on this stock if you decide to buy. Position-size accordingly. However, if you've done your homework and also see an opportunity here, consider Viking Therapeutics worthy of a speculative buy.Read NextMar 26, 2026 •By Rachel WarrenCan You Invest in Ozempic in 2026?

Everything You Need to KnowMar 23, 2026 •By David Jagielski, CPAWhy Viking Therapeutics Stock Could Take Off Later This YearMar 16, 2026 •By Jonathan PoncianoWhat to Know About This Obesity Drug Developer That Just Drew a New $7 Million InvestmentMar 11, 2026 •By Lee SamahaHere's Why Viking Therapeutics Stock Recovered and Can Soar in 2026Mar 9, 2026 •By Prosper Junior BakinyForget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall StreetMar 29, 2026 •By Keithen DruryPrediction: This Will Be Nvidia's Stock Price 3 Years From NowAbout the AuthorThomas Niel is a contributing Analyst at The Motley Fool, covering publicly traded companies in the consumer goods and technology sectors. Prior to the Motley Fool, Thomas was a contributing Analyst for several online investing publications, including InvestorPlace, Seeking Alpha, and TipRanks. He also has past career experience in the accounting and government contracting industries. He holds a B.B.A. in Accounting from Marymount University. Thomas won his school's geography bee in the fifth grade, but retired from the professional geography bee circuit shortly thereafter.TMFThomasNielStocks MentionedViking TherapeuticsNASDAQ: VKTX$32.52(-5.05%)-$1.73Eli LillyNYSE: LLY$878.24(-2.09%)-$18.76PfizerNYSE: PFE$27.06(-1.87%)-$0.52Novo NordiskNYSE: NVO$36.01(-1.07%)-$0.39*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.